MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test.

ADALIMUMAB; ARTHRITIS; DRUGS; JOINT diseases; ALZHEIMER'S disease

MoonLake Immunotherapeutics, a biotech company, saw its stock rise after its experimental psoriatic arthritis treatment, sonelokimab, outperformed AbbVie's Humira in a 24-week study. Sonelokimab also appeared to be more effective than UCB's bimekizumab, which is also being tested for this use. MoonLake is also testing sonelokimab in patients with hidradenitis suppurativa (HS), a condition that causes skin lesions. The company expects the HS market to grow to $10 billion to $15 billion by 2031. MoonLake plans to meet with the FDA in the second quarter and start Phase 3 studies in the second half of the year. [Extracted from the article]

Copyright of Investors Business Daily is the property of Investor's Business Daily and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)